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The neglected tropical disease leishmaniasis is caused by species of the genus Leishmania, which are single-celled eukaryotic parasites transmitted by phlebotomine sand flies (1, 2).
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Leishmaniasis occurs in many regions of the world, with more
than 12 million cases and more than 1.7 billion people at risk (1,
3). Three clinical presentations are most common: mild, selfhealing cutaneous lesions (cutaneous leishmaniasis or CL),2
fatal visceral disease, and disfiguring metastatic forms such as
mucocutaneous leishmaniasis (MCL) (4). The factors determining disease progression and responsiveness to treatment
are unclear, but are thought to be both host- and pathogenderived (5, 6).
Many isolates of Leishmania within the subgenus Viannia,
including Leishmania braziliensis (Lbr) and Leishmania guyanensis (Lgy), bear Leishmaniavirus, a single-segmented dsRNA
Totivirus known as Leishmania RNA virus 1 (LRV1) (5, 7–9).
Like most other Totiviridae species, LRV1 is neither shed nor
infectious and is inherited vertically (10, 11); indeed, phylogenetic evidence suggests that LRV1 strains have persisted and
co-evolved with their Leishmania hosts over millions of years
(10).
Previous work has established that mice infected with parasites containing the endobiont LRV1 exhibit greater pathology,
higher parasite numbers, and increased metastasis (12, 13).
These studies benefited from the availability of isogenic LRV1⫹
or LRV1⫺ lines, generated spontaneously or by defined methods such as RNAi or antiviral drug treatment (14 –16).
The role of LRV1 in human leishmaniasis has been more
challenging to establish definitively. When comparing rates of
CL and MCL, some studies find that LRV1⫹ strains generate
more MCL (17–19), whereas others do not (20, 21). These discrepant findings may be explained by other parasite or host
factors known to contribute to MCL pathology (13, 22, 23).
Furthermore, differences in the severity of disease are not
always accurately captured by binary categorization as CL or
MCL. Moreover, co-infections with viruses inducing Type I
interferon responses exacerbate Lgy pathology and metastasis
(24, 25), potentially obscuring the contributions of LRV1.
Importantly, the presence of LRV1 in clinical isolates of Lbr or
Lgy correlates with drug treatment failure and relapses (18, 20),
which could be explained by the increased parasite numbers or
altered host responses predicted from animal models (12, 13,
2

The abbreviations used are: CL, cutaneous leishmaniasis; MCL, mucocutaneous leishmaniasis; Lgy, Leishmania guyanensis; Lbr, Leishmania braziliensis; LRV1, Leishmania RNA virus 1; 2CMA, 2⬘-C-methyladenosine; 2CMA-TP,
2⬘-C-methyladenosine triphosphate; RDRP, RNA-dependent RNA polymerase; 7d2CMA, 7-deaza-2⬘-C-methyladenosine; LD, low-density; MD, medium-density; HD, high-density.

6460 J. Biol. Chem. (2018) 293(17) 6460 –6469
© 2018 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.

Downloaded from http://www.jbc.org/ at Washington University on November 20, 2019

Leishmania is a widespread trypanosomatid protozoan parasite causing significant morbidity and mortality in humans. The
endobiont dsRNA virus Leishmania RNA virus 1 (LRV1) chronically infects some strains, where it increases parasite numbers
and virulence in murine leishmaniasis models, and correlates
with increased treatment failure in human disease. Previously,
we reported that 2ⴕ-C-methyladenosine (2CMA) potently inhibited LRV1 in Leishmania guyanensis (Lgy) and Leishmania braziliensis, leading to viral eradication at concentrations above 10
M. Here we probed the cellular mechanisms of 2CMA inhibition, involving metabolism, accumulation, and inhibition of the
viral RNA-dependent RNA polymerase (RDRP). Activation
to 2CMA triphosphate (2CMA-TP) was required, as 2CMA
showed no inhibition of RDRP activity from virions purified on
cesium chloride gradients. In contrast, 2CMA-TP showed IC50
values ranging from 150 to 910 M, depending on the CsCl density of the virion (empty, ssRNA-, and dsRNA-containing). Lgy
parasites incubated in vitro with 10 M 2CMA accumulated
2CMA-TP to 410 M, greater than the most sensitive RDRP IC50
measured. Quantitative modeling showed good agreement
between the degree of LRV1 RDRP inhibition and LRV1 levels.
These results establish that 2CMA activity is due to its conversion to 2CMA-TP, which accumulates to levels that inhibit
RDRP and cause LRV1 loss. This attests to the impact of the
Leishmania purine uptake and metabolism pathways, which
allow even a weak RDRP inhibitor to effectively eradicate LRV1
at micromolar concentrations. Future RDRP inhibitors with
increased potency may have potential therapeutic applications
for ameliorating the increased Leishmania pathogenicity conferred by LRV1.

2ⴕ-C-methyladenosine triphosphate inhibits LRV1 RDRP

Figure 2. Distribution of viral capsid protein across a CsCl density gradient. Clarified parasite lysates were separated on a CsCl density gradient and
the relative amounts of viral capsid protein in each fraction were measured
(black triangles; see “Experimental procedures”). The density of each fraction
(gray circles) was measured with an Abbe refractometer. Data for one representative gradient are shown out of the 7 performed. The low-, medium-, and
high-density “peak” fractions (LD, MD, and HD) taken for RDRP assays, are
labeled.

26). Overall, there is good reason to postulate a role for LRV1
in increasing disease severity in human leishmaniasis (13),
although many questions remain.
LRV1 follows a typical totiviral life cycle where the dsRNA
viral genome encodes two large overlapping reading frames, the
capsid and RNA-dependent RNA polymerase (RDRP) (Fig. 1A).
First, the dsRNA genome is transcribed by the viral RDRP into
positive-sense ssRNA. As in many totiviruses, the RDRP is
translated via a ⫹1 frameshift, generating a capsid–RDRP
fusion (27–29). The capsid monomers then self-assemble into
immature virions (30), incorporating the positive-sense ssRNA
transcript, which the RDRP then replicates into the mature
dsRNA genome.
Vaccination of mice using the LRV1 capsid results in significant protection against LRV1⫹ Lgy (31), suggesting that therapies targeting LRV1 specifically might aid in reducing disease
pathology. Previously, we reasoned that the powerful nucleoside and nucleobase salvage pathways of Leishmania might
enhance the efficacy of nucleosides analogs targeting the viral
RDRP (15, 32). Accordingly, screening a small library of antiviral nucleosides identified two closely-related adenosine analogs, 2⬘-C-methyladenosine (2CMA) and 7-deaza-2⬘-C-methyladenosine (7d2CMA) (Fig. 1B), which specifically inhibited
LRV1 replication in cultured Leishmania cells (15). These compounds exhibited EC50 values of 3–5 M for viral inhibition,
contrasting with much greater EC50 values for the parasites
themselves. The active compounds rapidly eradicated LRV1
when tested at concentrations above 10 M, allowing us to readily create isogenic LRV1⫺ lines (15).
Importantly, these were the first studies showing specific
inhibition of any totivirus. The mechanism of anti-LRV1 activ-

Results
Purification and separation of virion populations on CsCl
gradients
RDRP assays were carried out with Lgy strain M4147 LRV1
virions purified by CsCl equilibrium gradient centrifugation (7,
33). After fractionation, virions were detected and quantified by
their reactivity with an anti-capsid antibody. We reproducibly
observed three overlapping “peaks,” designated low-, medium-,
and high-density (LD, MD, and HD) (Fig. 2). In previous studies
of the yeast L-A Totivirus, similar peaks were shown to correspond to virions that were primarily “empty” or contained
ssRNA or dsRNA, respectively (34, 35). The densities of the Lgy
LRV1 LD, MD, and HD peaks were 1.29, 1.36, and 1.41 g/ml, in
good agreement with the densities of L-A virus particles bearing ssRNA and dsRNA (1.31 and 1.41 g/ml, respectively) (36).
Preliminary data from S1 nuclease digestion of viral RNA from
these fractions were consistent with these assignments.3
In vitro assay of LRV1 RDRP activity
To measure RDRP activity, purified virions were allowed to
incorporate [␣-32P]UTP in the presence of the other three
nucleoside triphosphates for 1 h, a time sufficient for one round
of viral genome replication (33). RNA was purified and separated by native gel electrophoresis, and the products were visualized and quantified. Two products were always found: one
about 5 kb, presumably corresponding to the full-length LRV1
genome, and smaller, heterogeneous products ranging from 0.1
3

J. I. Robinson, unpublished observations.
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Figure 1. Leishmania LRV1 replication cycle and inhibitors. A, a schematic
depiction of the LRV1 lifecycle. RNAs are indicated in color (⫹ strand, red;
⫺strand, blue); the dsRNA genome within the mature virion is shown as
straight lines, whereas ssRNAs are shown as jagged lines. The viral RDRP (black
trapezoid) is shown fused to a capsid monomer (white circle), as the RDRP is
generated through frameshift translation (27–29). B, chemical structures of
adenosine, 2⬘-C-methyladenosine, and 7-deaza-2⬘-C-methyladenosine.

ity was postulated to be through direct inhibition of the LRV1
RDRP by the triphosphorylated form of 2CMA. Here we provide support for this hypothesis, although the potency of
2CMA-TP for viral inhibition was unexpectedly weak. Remarkably, viral inhibition was accomplished through hyper-accumulation and retention of 2CMA-TP, arising from the powerful
uptake and metabolic salvage pathways of these purine auxotrophs (32). These findings have significant implications for
future efforts aimed toward developing new and more potent
Leishmania virus inhibitors.

2ⴕ-C-methyladenosine triphosphate inhibits LRV1 RDRP

Figure 3. Radiolabeled RNAs produced by purified Lgy LRV1 RDRP in
vitro. A, RDRP activity in LD, MD, and HD fractions (Fig. 2) was assayed by
[␣-32P]UTP incorporation, as described under “Experimental procedures.”
Radiolabeled RNAs were run along-side pure [␣-32P]UTP on a native agarose
gel. The full-length and small RDRP products are labeled for reference. B,
RDRP reactions were performed in the presence of 0, 10, 30, 100, 300, or 600
M 2CMA-TP. As a negative control, the RDRP reaction was run using a mock
HD fraction isolated from LRV1⫺ Lgy parasites. A representative titration
using the HD fraction is shown here out of the 4 HD fraction titrations
performed.

to 0.5 kb, which we considered abortive transcripts (Fig. 3A).
Neither extending the incubation time nor increasing the concentration of UTP significantly altered the profile obtained.3
Importantly, neither full-length nor small products were produced by corresponding preparations from LRV1-negative parasites (Fig. 3B).
2CMA-TP specifically inhibits viral RDRP activity
Incubation of the three LRV1 fractions with 2CMA-TP
reduced synthesis of both the full-length and small RDRP products (Figs. 3–5). The synthesis of each product was quantitated
and normalized to that obtained with drug-free controls. IC50
values were calculated by fitting the inhibition data with a logistic dose-response curve (Table 1). These ranged from 150 M
for full-length product synthesis by LD virions to 910 M for
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Figure 5. Specificity of Lgy RDRP inhibition by 2CMA-TP relative to
2CMA and dATP. RDRP reactions were performed for 1 h in the presence
of 1 mM 2CMA, 600 M dATP, or 600 M 2CMA-TP. The amount of fulllength (top panel) and small products (bottom panel) were measured and
normalized to untreated control reactions. Individual values are shown for
two experiments (with 1 or 2 technical replicas) and the means are marked
with horizontal lines.

small products synthesized by HD virions (Table 1, Figs. 3 and
4). These IC50 values were unexpectedly high, greatly exceeding
the extracellular concentration of 2CMA shown previously to
cause 50% inhibition of LRV1 abundance (⬃3 M) (15). This did
not arise artificially from 2CMA-TP degradation during the

Downloaded from http://www.jbc.org/ at Washington University on November 20, 2019

Figure 4. 2CMA-TP inhibition of RDRP activity of purified Lgy LRV1 virions. The amounts of full-length or small RDRP products were quantified and
then normalized to the amount of product formed in the absence of 2CMATP. The averages and S.D. values (calculated with Microsoft Excel) from three
LD virion titrations () and four HD virion titrations (Œ) are shown. Doseresponse curves for LD (dotted line) and HD virions (solid line) were fitted using
the drc package in R (68). A, plot of full-length RDRP products. B, plot of small
RDRP products. MD virions showed intermediate profiles3 (Table 1).

2ⴕ-C-methyladenosine triphosphate inhibits LRV1 RDRP
Table 1
Effect of 2CMA-TP on Lgy LRV1 RDRP activity
IC50 values and 95% confidence intervals for the inhibition of full-length and small
RDRP product synthesis were calculated by simultaneously fitting RDRP inhibition
data for each RDRP product and virion population to logistic dose-response curves
(drc package in R (68)). Because the RDRP activity was normalized with no activity
set as zero, we fixed the minimum parameter to zero. The influence of RDRP product type and virion population on the IC50 values was estimated by fitting doseresponse curves while combining all RDRP products or virion populations. Comparing these submodels to the full model using analysis of variance (68) showed that
virion type contributes significantly to the goodness-of-fit (p ⬍ 0.001), whereas the
RDRP product contribution was only borderline significant (p ⬍ 0.05) (72).
LRV1 fraction IC50
Product

Low-density
(n ⴝ 3)

Full-length
Small

150 (90–210)
250 (160–330)

Medium-density
(n ⴝ 3)

High-density
(n ⴝ 4)

M

250 (100–400)
640 (300–980)

420 (310–540)
910 (620–1200)

2CMA activation to 2CMA-TP within parasites
To account for the relative sensitivity of Lgy LRV1 within
cells to 2CMA treatment compared with the insensitivity of
LRV1 RDRP activity to inhibition by 2CMA-TP, we hypothesized that parasites must acquire and activate 2CMA, accumulating high 2CMA-TP concentrations. We developed an
HPLC protocol capable of resolving synthetic 2CMA-TP
from natural ribonucleotides and the internal standard,
dGTP (Fig. 6, A and B; a small peak presumed to be
2CMA-DP was also observed). Although dGTP occurs naturally, its intracellular concentration of ⬃5 M is well below the
limit of detection for this assay and thus does not interfere with
its use for this purpose (37). Standard mixtures were then used
to generate a calibration curve relating peak area to 2CMA-TP
amount.
We next evaluated several protocols for extracting parasite
nucleotides and determined that extraction with 1:1 acetonitrile:water performed best, as judged by recovery of the added
dGTP standard (“Experimental procedures”). We then compared the nucleotide profiles of LRV1⫹ Lgy grown in the presence or absence of 10 M extracellular 2CMA for 20 h, a time
corresponding to more than two rounds of parasite replication.
Under these conditions, we observed a peak co-eluting with
synthetic 2CMA-TP that was absent from untreated parasites
(Fig. 6B). This established the parasite’s capacity to activate
2CMA to 2CMA-TP.

Figure 6. Lgy M4147 LRV1ⴙ parasites synthesize 2CMA-TP. A, standard
mixture of dGTP, ATP, and 2CMA-TP establishing the HPLC elution profile of
2CMA-TP relative to dGTP, the exogenous internal standard (endogenous
cellular dGTP concentrations are well below the limit of detection). The small
peak eluting between dGTP and ATP is presumed to be 2CMA-DP. B, detection of 2CMA-TP in Lgy incubated with 10 M 2CMA for 20 h (blue line). An
extract from cells grown without drug (gray line) is provided for comparison.
To correct for variation in extraction efficiency and HPLC elution times, Lgy
samples had 7 nmol of dGTP spiked in immediately prior to extraction.

Time and external 2CMA concentration dependence of
2CMA-TP accumulation
Leishmania cell volumes vary somewhat depending on the
culture’s growth phase (38). To calculate the intracellular
2CMA-TP concentration, we therefore determined the average
volume of Lgy parasites under our assay conditions. In logarithmic growth phase, parasite volumes averaged about 23 femtoliters (“Experimental procedures”).
We measured the intracellular concentration of 2CMA-TP
as a function of time of incubation with 10 M external 2CMA.
Within 1.5 h, 2CMA-TP levels had risen to concentrations
comparable with the minimal RDRP IC50 levels (Fig. 7A), and
had reached maximal levels by 8 h.
We then measured the intracellular 2CMA-TP levels following growth in varying levels of 2CMA for 20 h (Fig. 7B). The
concentrations were chosen to span a range from noninhibitory
(1 M) to that sufficient to eradicate LRV1 entirely (10 M) (15).
Over this range of concentrations, internal 2CMA-TP levels
exceeded external 2CMA concentrations by 40- to 80-fold (Fig.
7B).
When propagated in the subinhibitory dose of 2CMA (1 M),
the intracellular 2CMA-TP concentration was 78 ⫾ 9 M (Fig.
7B, n ⫽ 4), well below the minimal IC50 for RDRP inhibition
(150 M for full-length products from LD virions; Table 1).
When treated with 3 M external 2CMA, the EC50 for LRV1
inhibition, intracellular 2CMA-TP levels rose to 152 ⫾ 43 M
(n ⫽ 4), comparable with the minimal RDRP IC50. Finally, cells
propagated in 10 M external 2CMA reached an intracellular
2CMA-TP concentration of 410 ⫾ 110 M (n ⫽ 4) (Fig. 7B),
well in excess of the minimum IC50 for RDRP inhibition. Thus,
with increasing external 2CMA, the steady-state levels of intraJ. Biol. Chem. (2018) 293(17) 6460 –6469
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assay, as HPLC tests of RDRP reactions showed only 3.7 ⫾ 0.6%
(n ⫽ 3) loss of 2CMA-TP.
As anticipated, 2CMA did not measurably inhibit RDRP
activity when tested at concentrations up to 1000 M (Fig. 5).
Similarly, dATP, which lacks both the 2⬘-hydroxyl and methyl
groups of 2CMA (Fig. 1B), failed to inhibit RDRP activity at the
highest concentration tested (600 M; Fig. 5); nor in limited
tests did 600 –1000 M TTP inhibit.3 These data show that high
concentrations of a nonsubstrate nucleoside triphosphate do
not inhibit RDRP activity nonspecifically. Together, these data
suggest that despite its relatively low potency, under these assay
conditions 2CMA-TP inhibition of LRV1 RDRP activity was
specific.

2ⴕ-C-methyladenosine triphosphate inhibits LRV1 RDRP

Figure 7. L. guyanensis parasites accumulate high levels of 2CMA-TP.
Intracellular 2CMA-TP was extracted and quantified by HPLC (Fig. 6; File S2)
and its concentration was calculated using the measured cell volume of 23
femtoliters under these conditions (“Experimental procedures”). Each replicate (gray circles) was obtained from a separate 5-ml culture grown in Schneider’s medium. Averages and S.D. (black diamonds; calculated in Microsoft
Excel) are also plotted for each time point or condition. For reference, the
minimum RDRP IC50 is marked on each graph (green dashed line). A, 2CMA-TP
accumulation in parasites measured over time. Lgy parasites were incubated
in 10 M 2CMA for the indicated periods and 108 cells were harvested for
analysis. This experiment was performed twice. Intracellular 2CMA-TP concentrations at equilibrium after 20 h of incubation with 10 M 2CMA are also
plotted (gray triangles). B, steady-state concentrations of 2CMA-TP vary with
2CMA dose. Lgy parasites were grown for 20 h in the presence of the indicated
concentrations of external 2CMA prior to analysis. This experiment was
repeated four times. The fold-concentration of intracellular 2CMA-TP was calculated relative to extracellular 2CMA dose (blue diamonds). For reference, the
EC50 for LRV1 inhibition in parasites is marked on the X axis (black arrow). C,
retention of 2CMA-TP following removal of 2CMA. LRV1⫹ Lgy M4147 parasites were incubated for 20 h in the presence of 10 M 2CMA; at that time, cells
were harvested, washed, and resuspended in drug-free medium. Intracellular
2CMA-TP levels were determined after incubation for the indicated times. To
correct for 2CMA-TP dilution due to parasite replication, 2CMA-TP concentrations were multiplied by the fold-population growth due to 2CMA removal
(about 1.4-fold over the course of the experiment). This experiment was
repeated twice using two independent cultures per time point (n ⫽ 4; gray
circles). Averages and S.D. (black diamonds; calculated in Microsoft Excel) are
also plotted for each time point. Because some time points were collected at
slightly varying times, these were averaged for plotting in the figure.

cellular 2CMA-TP rose progressively to values exceeding the
minimal RDRP IC50, which in turn corresponded reasonably
well to the observed effects on LRV1 inhibition.
Parasites retain 2CMA-TP for an extended period following
2CMA removal
Once phosphorylated by cells, some nucleoside analogs are
retained for an extended period as triphosphates, thereby contributing significantly to drug efficacy (39). To assess this, Lgy
parasites were incubated for 20 h in 10 M 2CMA, washed, and
resuspended in drug-free medium, after which intracellular
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2CMA-TP levels were measured and corrected for parasite replication (Fig. 7C). Even after 8 h, 2CMA-TP levels remained at
or above the minimal RDRP IC50. Indeed, the persistence of
intracellular parasite 2CMA-TP greatly exceeded that of serum
2CMA measured in mammalian models (40).
A quantitative simulation of RDRP and virus inhibition
We asked whether a simple computational model using the
relative rates of parasite and viral replication under conditions
of drug treatment could quantitatively simulate the experimental data above. We developed a model employing Gibson and
Bruck’s next reaction modification to Gillespie’s stochastic simulation algorithm (41), which directly simulates the occurrence
of individual events over time by picking the next event time
from an associated probability distribution (“Experimental procedures”; supporting File S2).
In this model, the relevant parameters were parasite and
virus replication rates. We used the experimentally-measured
parasite population doubling time of 7.5 h and assumed that in
the absence of drug pressure the relative parasite and virus replication rates were identical. Simulations began with an initial
population of 1000 cells, a number large enough that repeated
simulations deviated ⬍1% from each other. The simulated parasites each initially contained 16 LRV1 particles, consistent
with prior measurements of virus numbers (15). Using these
conditions, the simulation correctly maintained the LRV1 population over time at an average of 16 virions per parasite in the
absence of drug pressure (Fig. 8).
The effect of 2CMA was then modeled by adjusting the ratio
of LRV1 to parasite replication rates (RV:RP). Importantly, at
concentrations relevant to these studies, 2CMA has little effect
on the growth of the parasite itself (15). After setting RV:RP to
1:2, 1:3, or 1:4, LRV1 was now rapidly lost (Fig. 8). Comparison
of the simulations with RV:RP of 1:3 or 1:4 showed close correspondence with the experimentally-measured rate of LRV1 loss
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Figure 8. Gillespie simulation of LRV1 loss during 2CMA treatment. Plots
of simulated, theoretical, and experimental results showing the number of
LRV1 virions per cell as a function of cell doubling are shown. Gillespie simulations were performed assuming relative inhibition of LRV1 and parasite
replication (RV:RP) to be between 1:1 and 1:4 are depicted by blue lines. These
lines represent averages and S.D. of 6 identical simulations (Excel). A theoretical plot is show (gray dotted line) for total inhibition of viral replication with
ideal 2-fold viral dilution per population doubling time. Two experimental
data sets from Kuhlmann et al. (15) measuring LRV1 loss during 2CMA treatment are shown as black dashed lines.

2ⴕ-C-methyladenosine triphosphate inhibits LRV1 RDRP

Discussion
Previously, we showed that two 2⬘-C-methyladenosine analogs selectively inhibit the replication of Lgy and Lbr LRV1 but
have significantly less effect on the parasite growth rates. These
compounds were the first such inhibitors to be described for
any totivirus (15). There, the mechanism of action was presumed but not shown to follow the classic antiviral nucleoside
paradigm of uptake, conversion to the nucleoside triphosphate,
and inhibition of the viral RDRP. In this study, we provide evidence that this is in fact the case for Lgy LRV1 inhibition following 2CMA treatment. Importantly, the ability of the parasite
to accumulate high levels of 2CMA-TP (Fig. 7) was strongly
correlated with viral elimination at concentrations above 3 M
external 2CMA (15). These data provide key information for
the design of other improved LRV1 inhibitors with greater
potential for use as therapeutics.
We first established an assay for RDRP activity from purified
virions, separated on CsCl gradients to obtain virions in different stages of maturation (Figs. 1–3). RDRP activity depended
on the presence of LRV1 and yielded two major products, corresponding to the full-length viral genome as well as a heterogeneous collection of small and presumably abortive transcripts (Fig. 3). Quantitative analysis showed that the IC50
values for full-length product synthesis were somewhat lower
than those measured for small product synthesis (p ⬍ 0.05), and
significantly less for low-density virions than high (p ⬍ 0.001;
Table 1). These may reflect the intrinsic sensitivities of the
RDRP activity within mature and immature viral particles,
perhaps related to the distinct transcriptase/positive-strand
(mRNA) and replicase/negative-strand synthesis activities.
This is the first such report for totiviruses, for which antiviral
drugs have only recently been reported (15). Differential effects
on replicase versus transcriptase activity have also been seen in
reoviruses, where ribavirin triphosphate inhibits replicase but
not transcriptase activity (42). Our studies were constrained by
two factors: first, the virion-based RDRP assay depends on

native RNA substrates, and second, the virion-containing fractions used were not homogeneous (Fig. 2). This prevented clean
separation of RDRP transcription and replication activities, and
precluded the use of tightly-controlled initiation and elongation assays, required for determination of the precise mechanism of RDRP inhibition by 2CMA-TP. Future studies with
purified RDRP and defined RNA substrates will be required to
fully elucidate the mechanism of action of 2CMA-TP.
2CMA was completely inactive for RDRP inhibition, as were
dATP or TTP, structurally similar nonsubstrate nucleoside
triphosphates (Fig. 5). Activation to triphosphate form is common and often rate-limiting among nucleoside analog drugs
(43–45). It was also shown previously that the triphosphate
form of 2CMA, but not the analog itself, is active against the
hepatitis C virus RNA polymerase (46).
Despite the ability of 2CMA to clear LRV1 from parasites
grown in micromolar concentrations of drug (15), 2CMA-TP
inhibition of LRV1 RDRP activity was not very potent, with IC50
values ranging upwards of 150 M (Table 1). We resolved this
discrepancy by showing that the parasites avidly scavenged
2CMA from the medium and efficiently converted it to the
active triphosphate form (Fig. 6), reaching intracellular
2CMA-TP concentrations more than 40-fold that of extracellular 2CMA (Fig. 7). This likely reflects the fact that as
purine auxotrophs, Leishmania parasites must avidly scavenge all naturally occurring purines from their environment,
through a combination of powerful transporters and metabolic interconversions (32). One particularly important step
for 2CMA and related inhibitors may be adenosine kinase
(47, 48), which may mediate the initial and often rate-limiting phosphorylation of antiviral nucleosides (44, 49). Strong
accumulation of toxic anti-leishmanial purines has also been
noted in earlier studies (50, 51). Thus the salvage pathway
converts 2CMA into a potent tool for eliminating the virus.
Importantly, the accumulated levels of intracellular 2CMA-TP
closely matched the consequences of RDRP inhibition and LRV1
loss. When grown in 10 M external 2CMA, internal 2CMA-TP
levels greater than 400 M were attained, well over the minimal
LRV1 RDRP IC50 (Table 1). In contrast, at 1 M external 2CMA,
internal 2CMA-TP concentrations were only 80 M, well below
that needed for RDRP inhibition, and little effect was seen on
LRV1 levels (15). These experimental observations were corroborated using Gillespie (52) simulation to model LRV1 loss (Fig. 8).
Our studies did not examine other potential 2CMA-TP targets
such as the capsid endonuclease (53–57) and could not discern the
exact mechanism of RDRP inhibition by 2CMA-TP. Nevertheless,
these analyses show that the elimination of LRV1 by 2CMA can be
largely explained through the direct inhibition of LRV1 RDRP
activity by 2CMA-TP.
Previously, we proposed that treatments targeting LRV1
could be used therapeutically to ameliorate the severity of Lgy
and Lbr infections (15, 31). 2CMA-TP accumulates rapidly to
inhibitory concentrations within 1–2 h of 2CMA exposure, and
once formed, is retained at inhibitory concentrations for ⬎8 h
(Fig. 7). This suggests that a relatively short period of treatment
may lead to a prolonged period of viral inhibition. In animal
models, 2CMA has a short serum half-life, which precludes its
use in humans or animals. The serum half-life of 7d2CMA,
J. Biol. Chem. (2018) 293(17) 6460 –6469
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under 2CMA inhibition (15) (Fig. 8; solid lines, simulation;
dashed lines, experimental).
To compare these predictions with our experimental data on
parasite replication and RDRP inhibition, we made an initial
simplifying assumption that the primary determinant of LRV1
replication would be the lowest RDRP 2CMA-TP IC50 value
(150 M, for full-length product synthesis by LD virions; Table
1; Fig. 4A). Because RDRP inhibition would reduce viral RNA
levels within infected cells, RDRP activity would likely become
rate-limiting at high 2CMA-TP concentrations. We then calculated the 2CMA-TP concentrations required to give RV:RP of
1:2, 1:3, or 1:4. Importantly, at 10 M extracellular 2CMA, intracellular 2CMA-TP is 410 M, and RV:RP was calculated to be
⬃1:3 (Fig. 8). Thus the simulation and experimental data are in
good agreement about the quantitative and qualitative aspects
of RDRP inhibition and viral loss. This suggests that despite the
potential complexity of viral replication, the system behaves as
RDRP activity is rate-limiting for viral replication and that our
in vitro measurements of 2CMA-TP inhibition are consistent
with our in vivo measurements of viral elimination time
courses.

2ⴕ-C-methyladenosine triphosphate inhibits LRV1 RDRP

Experimental procedures
Parasite strains and media
Luciferase-expressing isogenic clones of L. guyanensis strain
M4147 (MHOM/BR/75/M4147) were utilized for these studies.
LRV1⫹ clone LgyM4147/SSU:IR2SAT-LUC(b)c3 and LRV1⫺
clone LgyM4147/pX63HYG/SSU:IR2SAT-LUC(b)c4 were
described previously (63). For some experiments a LgyM4147/
LRV1⫹ line expressing GFP⫹ (LgyM4147/SSU:IR2SATLUC(b)c3/SSU:IR3HYG-GFP⫹(b)) was used (provided by E.
Brettmann). Schneider’s medium (Sigma) was prepared following the manufacturer’s instructions, supplemented with 10%
heat-inactivated FBS, 0.76 mM hemin, 2 g/ml of biopterin, 50
units/ml of penicillin, and 50 g/ml of streptomycin, and
adjusted to a final pH of 6.5. M199 medium was prepared with
2% heat-inactivated FBS, 2% filter-sterilized human urine, 0.1
mM adenine, 1 g/ml of biotin, 5 g/ml of hemin, 2 g/ml of
biopterin, 50 units/ml of penicillin, 50 g/ml of streptomycin,
and 40 mM HEPES, pH 7.4 (64). No significant differences were
observed in the properties of virus preparations from either
medium. Cells were counted using either a hemocytometer or a
Coulter counter (BD Bioscience).
Purification and fraction of virions on CsCl gradients
Parasites were grown to early stationary phase in M199 or
Schneider’s medium (3 ⫻ 107 or 9 ⫻ 107 cells/ml, respectively).
1 ⫻ 1010 cells were pelleted at 2200 ⫻ g for 15 min at 4 °C and
washed twice with 10 ml ice-cold TMN buffer (100 mM Tris, pH
7.5, 50 mM MgCl2, 1.5 M NaCl). Cells were then resuspended in
1 ml of ice-cold lysis buffer (TMN buffer plus 1 mM DTT, 1⫻
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Complete protease inhibitor mixture (Roche Applied Science)
and 1% (v/v) Triton X-100), homogenized by pipetting 10 –12
times with a 1-ml micropipette, and incubated on ice for 20 –30
min. Lysis was completed by passing the mixture repeatedly
through a 27-guage needle, after which it was clarified by centrifugation at 15,000 ⫻ g for 10 min at 4 °C. Density gradients
were prepared by thoroughly mixing the clarified lysates with
enough 10 ⫻ TMN buffer, saturated CsCl, and distilled water to
make 12 ml of solution at a final density of 1.35 g/ml (2.82 M
CsCl). Gradients were spun in a pre-chilled SW41Ti rotor
(Beckman) at 32,000 rpm and 4 °C for ⬃72 h. Twelve 1-ml fractions were recovered immediately from each gradient using a
density gradient fractionator (ISCO).
The distribution of capsid protein across each gradient was
determined by binding of 50-l aliquots of each fraction to a
nitrocellulose membrane using a Mini-fold II Slot-Blot System
(Schleicher & Schuell, Keane, NH). The membrane was incubated on a roller with blocking buffer (2% nonfat powdered milk
in PBS) for 1 h, then stained with 1:2500 rabbit anti-capsid
antibody (65) in blocking buffer plus 0.2% Tween 20 (TWEEN
buffer) for another hour. The membrane was then washed 3
times for 5 min in 1⫻ PBS plus 0.1% Tween 20 (PBST). Membranes were next incubated in TWEEN buffer for 1 h with
1:10,000 goat anti-rabbit antibodies conjugated to IRDye 680
(LiCor Biosciences). Finally, the membranes were washed 3
times in PBST and once in PBS. Membranes were scanned with
an Odyssey IR Imaging System (LiCor Biosciences). The density of each fraction was measured by taking its refractive index
with an Abbe refractometer (Bausch and Lomb) and converting
to density using published formulas (66). Gradient fractions of
interest (Fig. 2) were dialyzed twice against 1⫻ TMN and once
in 1⫻ TMN plus 20% glycerol (4 °C), reaching CsCl concentrations less than 2 M. Fractions were flash frozen and stored at
⫺80 °C prior to use.
RDRP assay
RDRP activity of purified virions was measured using an
[␣-32P]UTP incorporation assay described previously (33).
Briefly, 20-l reactions contained 10 mM Tris-HCl (pH 7.5), 150
mM NaCl, 3 mM MgCl2, 4 mM DTT, 50 M each ATP, CTP, and
GTP, 20 Ci of [␣-32P]UTP, and 10 l of virions. Reactions
were incubated at room temperature for 1 h and quenched by
addition of 350 l of TRIzol (Ambion). A corresponding gradient fraction from LRV1⫺ parasites was included as a negative
control in each set. RNA was purified using a Direct-Zol RNA
miniprep kit (Zymo Research) and run on a native 1.2%
agarose–TAE gel in a vertical gel apparatus (Owl Scientific)
along with dsDNA sizing standards. The standards lane was
excised and stained with ethidium bromide, whereas the radiolabeled products were detected by exposing an imaging plate
for 24 h and reading it with a FLA-5100 phosphoimager (Fuji).
The amount of radiolabeled UTP in each RDRP product was
quantified using the gel analysis tool in FIJI/ImageJ (67). Equivalent regions from the negative control reaction were also integrated to calculate the background (Fig. 3).
To study inhibition of the viral RDRP by 2CMA-TP, varying
amounts of the compound were added to standard RDRP reaction mixtures. 2CMA-TP was custom synthesized by Jena Bio-
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however, is markedly longer (0.3 versus 1.6 h (58)). Interestingly, 7d2CMA shows an EC50 against Zika virus in cultured
mammalian cells of about 10 M, and dosing regimens have
shown significant inhibition in animal models (59, 60). This
suggests it might likewise be possible to achieve inhibition of
LRV1 in vivo using 7d2CMA.
In future work, one priority will be the development of antiLRV1 agents with improved potency. Preliminary studies
expressing a promiscuous HSV TK gene within Leishmania did
not increase the spectrum of activity significantly for those analogs tested from our previous study (15),3 suggesting that the
lack of activity may reflect failure to inhibit the LRV1 RDRP
itself rather than insufficient activation to triphosphates. Similarly, we found that several immucillins shown previously to
inhibit Leishmania nucleoside hydrolases (Immucillin A,
DADMe-Immucillin A, Immucillin H, and DADMe-Immucillin H (61, 62)) had little effect on the potency of 2CMA.3 While
these immucillins are nucleoside analogs, they showed no inhibition of LRV1 levels when tested at concentrations up to 100
 M.3
Additional priorities will be identifying compounds with
more favorable pharmacokinetics and minimal toxicity against
the mammalian host cell. Thus, efforts focusing on improved
potency against the RDRP activity itself may prove most fruitful. Our work now sets the stage for future studies exploring the
possibility that improved LRV1-targeted therapies may ameliorate the pathology of those Leishmania species and strains that
bear this fascinating virus.

2ⴕ-C-methyladenosine triphosphate inhibits LRV1 RDRP

Measurement of parasite volumes
Cultures of WT or GFP-expressing LRV1⫹ Lgy M4147 were
seeded at 2 ⫻ 105 cells/ml and analyzed when they reached
early, mid, or late log phase. From each sample, one aliquot was
analyzed by light scattering on a flow-cytometer, whereas
another was immobilized by treatment with 20 mM sodium
azide and imaged by spinning-disk confocal microscopy (69).
Cell volumes were calculated using a custom ImageJ script (67)
(supporting File S1). A standard curve relating forward scattering intensity to measured volume was developed from these
data. Forward scattering intensity of parasites in our assay conditions was then measured and used to estimate the intracellular parasite volume.
Nucleotide extraction from Leishmania parasites
For each sample, 108 cells were collected by centrifugation at
2,200 ⫻ g, 4 °C for 5 min, re-suspended in 1 ml of ice-cold PBS
and re-centrifuged. The cell pellet was gently re-suspended in
100 l of ice-cold 0.5⫻ PBS plus 7 nmol of dGTP as a recovery
and elution standard. Cells were immediately lysed by rapidly
re-suspending in 900 l of ice-cold 5:4 acetonitrile:water mixture (70) and vortexing continuously for 5 min at 4 °C. Insoluble
debris was pelleted at 16,000 ⫻ g for 5 min and the clarified
extract was transferred to a fresh tube. The solvent was
removed by evaporation in a Savant SpeedVac concentrator
(Thermo Scientific) with the heater off and the vacuum pump
refrigeration on. Samples were re-suspended with 80 l of distilled water, flash frozen, and stored at ⫺80 °C prior to HPLC
analysis.
HPLC separation of nucleotides
Cell extracts were clarified by centrifuging for 2 min at
16,000 ⫻ g. Nucleoside di- and triphosphates were separated by
isocratic HPLC as previously described (71). Briefly, a 20-l
aliquot of clarified extract was injected onto a Zorbax SB-C18
column (5 m particle size, 250 ⫻ 4.6 mm, Agilent) and eluted
at 1 ml/min with 150 mM KH2PO4 (pH 6.0), 4.2 mM tetrabutylammonium hydroxide, and 5.4% methanol. Eluting compounds
were monitored by UV absorbance at 254 nm (Fig. 6). The elution times of nucleoside triphosphates as well as 2CMA and

2CMA-TP were determined by running them individually. A
minor peak present in each standard was presumed to represent the diphosphate form of that nucleoside. A mixture containing 200 M ATP, GTP, CTP, UTP, and dGTP was used
periodically to assess column performance. Peak areas were
integrated using Millenium32 software (Waters). Varying
amounts of ATP, 2CMA-TP, and dGTP standards were used to
construct a calibration curve relating peak areas to compound
amounts. Peak areas varied linearly with nucleotide amounts
injected down to 50 pmol.
Gillespie simulation of LRV1 inhibition
We modeled the effects of 2CMA treatment on LRV1 using
the next-reaction modification to the Gillespie algorithm (a
more detailed description as well as code is provided in supporting File S2) (41). The parameters used to define the system
were as follows: number of parasites, number of virions per
parasite, parasite growth rate, and virus replication rate. All
simulations were initialized with 1000 parasites and 16 virions
per cell. Each cell and virus was assigned an amount of time
remaining until it divided or replicated, respectively. Because
these delay times were composed of an unknown but large
number of elementary chemical reactions, they were selected
from Gaussian distributions about the mean parasite division
and virion replication times, rather than the Poisson distributions used for elementary reactions (41, 52). At each step, the
event with the shortest time remaining was selected, the simulation time incremented, and the model updated accordingly.
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